329 related articles for article (PubMed ID: 37298653)
1. Microbial Influences on Immune Checkpoint Inhibitor Response in Melanoma: The Interplay between Skin and Gut Microbiota.
Bouferraa Y; Fares C; Bou Zerdan M; Boyce Kennedy L
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298653
[TBL] [Abstract][Full Text] [Related]
2. Effect of Gut Microbiota-Derived Metabolites on Immune Checkpoint Inhibitor Therapy: Enemy or Friend?
Zhao H; Wang D; Zhang Z; Xian J; Bai X
Molecules; 2022 Jul; 27(15):. PubMed ID: 35956752
[TBL] [Abstract][Full Text] [Related]
3. Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition.
Guardamagna M; Berciano-Guerrero MA; Villaescusa-González B; Perez-Ruiz E; Oliver J; Lavado-Valenzuela R; Rueda-Dominguez A; Barragán I; Queipo-Ortuño MI
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233289
[TBL] [Abstract][Full Text] [Related]
4. The Microbiome in Advanced Melanoma: Where Are We Now?
Fortman DD; Hurd D; Davar D
Curr Oncol Rep; 2023 Sep; 25(9):997-1016. PubMed ID: 37269504
[TBL] [Abstract][Full Text] [Related]
5. The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges.
Bouferraa Y; Chedid A; Amhaz G; El Lakkiss A; Mukherji D; Temraz S; Shamseddine A
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360802
[TBL] [Abstract][Full Text] [Related]
6. The gut microbiome and melanoma: A review.
Makaranka S; Scutt F; Frixou M; Wensley KE; Sharma R; Greenhowe J
Exp Dermatol; 2022 Sep; 31(9):1292-1301. PubMed ID: 35793428
[TBL] [Abstract][Full Text] [Related]
7. TIGIT
Tsakmaklis A; Farowski F; Zenner R; Lesker TR; Strowig T; Schlößer H; Lehmann J; von Bergwelt-Baildon M; Mauch C; Schlaak M; Knuever J; Schweinsberg V; Heinzerling LM; Vehreschild MJGT
BMC Cancer; 2023 Nov; 23(1):1160. PubMed ID: 38017389
[TBL] [Abstract][Full Text] [Related]
8. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
Zhang C; Wang J; Sun Z; Cao Y; Mu Z; Ji X
Cancer Sci; 2021 Aug; 112(8):3005-3017. PubMed ID: 34028936
[TBL] [Abstract][Full Text] [Related]
9. Targeted modulation of gut and intra-tumor microbiota to improve the quality of immune checkpoint inhibitor responses.
Wang W; Fan J; Zhang C; Huang Y; Chen Y; Fu S; Wu J
Microbiol Res; 2024 May; 282():127668. PubMed ID: 38430889
[TBL] [Abstract][Full Text] [Related]
10. The multifaceted roles of common gut microbiota in immune checkpoint inhibitor-mediated colitis: From mechanism to clinical application.
Han X; Zang D; Liu D; Chen J
Front Immunol; 2022; 13():988849. PubMed ID: 36189293
[TBL] [Abstract][Full Text] [Related]
11. Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers.
McQuade JL; Ologun GO; Arora R; Wargo JA
Curr Oncol Rep; 2020 Jun; 22(7):74. PubMed ID: 32577835
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
Front Immunol; 2021; 12():669150. PubMed ID: 34267748
[TBL] [Abstract][Full Text] [Related]
13. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.
Dora D; Bokhari SMZ; Aloss K; Takacs P; Desnoix JZ; Szklenárik G; Hurley PD; Lohinai Z
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769093
[TBL] [Abstract][Full Text] [Related]
14. Gut microbiota interactions with antitumor immunity in colorectal cancer: From understanding to application.
Zhuang YP; Zhou HL; Chen HB; Zheng MY; Liang YW; Gu YT; Li WT; Qiu WL; Zhou HG
Biomed Pharmacother; 2023 Sep; 165():115040. PubMed ID: 37364479
[TBL] [Abstract][Full Text] [Related]
15. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
[TBL] [Abstract][Full Text] [Related]
16. Gut microbiota: impacts on gastrointestinal cancer immunotherapy.
Lau HCH; Sung JJ; Yu J
Gut Microbes; 2021; 13(1):1-21. PubMed ID: 33435800
[TBL] [Abstract][Full Text] [Related]
17. The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors.
Joachim L; Göttert S; Sax A; Steiger K; Neuhaus K; Heinrich P; Fan K; Orberg ET; Kleigrewe K; Ruland J; Bassermann F; Herr W; Posch C; Heidegger S; Poeck H
EBioMedicine; 2023 Nov; 97():104834. PubMed ID: 37865045
[TBL] [Abstract][Full Text] [Related]
18. The cure from within? a review of the microbiome and diet in melanoma.
Kumar P; Brazel D; DeRogatis J; Valerin JBG; Whiteson K; Chow WA; Tinoco R; Moyers JT
Cancer Metastasis Rev; 2022 Jun; 41(2):261-280. PubMed ID: 35474500
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic interventions and mechanisms associated with gut microbiota-mediated modulation of immune checkpoint inhibitor responses.
Wong MK; Barbulescu P; Coburn B; Reguera-Nuñez E
Microbes Infect; 2021; 23(6-7):104804. PubMed ID: 33652120
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiota shed new light on the management of immune-related adverse events.
Tan B; Liu YX; Tang H; Chen D; Xu Y; Chen MJ; Li Y; Wang MZ; Qian JM
Thorac Cancer; 2022 Oct; 13(19):2681-2691. PubMed ID: 36043345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
